Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond
Viruses · 17.09.2024 · 16 (9) · 1476
DOI: 10.3390/v16091476 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 17.09.2024. Verfasst von Jane Y Chang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Ascendant Biotech Inc., Foster City, CA 94404, USA. Hauptthemen laut MEDLINE: Herpes Simplex, Herpes Simplex Virus Vaccines, Vaccination, Simplexvirus. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Herpes simplex virus (HSV) has coevolved with Homo sapiens for over 100,000 years, maintaining a tenacious presence by establishing lifelong, incurable infections in over half the human population. As of 2024, an effective prophylactic or therapeutic vaccine for HSV remains elusive. In this review, we independently screened PubMed, EMBASE, Medline, and Google Scholar for clinically relevant articles on HSV vaccines. We identified 12 vaccines from our literature review and found promising candidates across various classes, including subunit vaccines, live vaccines, DNA vaccines, and mRNA vaccines. Notably, several vaccines—SL-V20, HF10, VC2, and mRNA-1608—have shown promising preclinical results, suggesting that an effective HSV vaccine may be within reach. Additionally, several other vaccines such as GEN-003 (a subunit vaccine from Genocea), HerpV (a subunit vaccine from Agenus), 0ΔNLS/RVx201 (a live-attenuated replication-competent vaccine from Rational Vaccines), HSV 529 (a replication-defective vaccine from Sanofi Pasteur), and COR-1 (a DNA-based vaccine from Anteris Technologies) have demonstrated potential in clinical trials. However, GEN-003 and HerpV have not advanced further despite promising results. Continued progress with these candidates brings us closer to a significant breakthrough in preventing and treating HSV infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ascendant Biotech Inc., Foster City, CA 94404, USA.
- Bioscience Advising, Cincinnati, OH 45208, USA.
- Department of Microbiology, Blavatnik Institute, Harvard Medical School, Boston, MA 02115, USA.
ORCID-Profile: Jane Y Chang, Hyung Suk Oh
Zitieren
APA
Chang, J. Y., Balch, C., & Oh, H. S. (2024). Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond. Viruses, 16(9), 1476. https://doi.org/10.3390/v16091476
Vancouver
Chang JY, Balch C, Oh HS. Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond. Viruses. 2024;16(9):1476. doi:10.3390/v16091476
BibTeX
@article{Chang2024,
author = {Chang, Jane Y and Balch, Curt and Oh, Hyung Suk},
title = {Toward the Eradication of Herpes Simplex Virus: Vaccination and Beyond},
journal = {Viruses},
year = {2024},
volume = {16},
number = {9},
pages = {1476},
doi = {10.3390/v16091476}
}
EUVIMED